Phase II: Combination of cladribine, cyclophosphamide, mitoxantrone, rituximab (R-CCM) in patients with relapsed and refractory follicular and mantle cell lymphoma, results of a prospective study at Kitasato University

Yuhko Suzuki,Mikio Danbara,Miyuki Hayama,Tomiteru Togano,Manabu Ohsaka,Koji Miyazaki,Ryoichi Horie,Masaaki Higashihara

Phase II: Combination of cladribine, cyclophosphamide, mitoxantrone, rituximab (R-CCM) in patients with relapsed and refractory follicular and mantle cell lymphoma, results of a prospective study at Kitasato University

2007

Yuhko Suzuki
Mikio Danbara
Miyuki Hayama
Tomiteru Togano
Manabu Ohsaka
Koji Miyazaki
Ryoichi Horie
Masaaki Higashihara

18542 Background: Indolent non-Hodgkin’s lymphoma (I-NHL) account for 20% of all of NHL in Japan, and they are increasing in number. More than 80% of the patients who achieve a complete remission w...

Keywords:

Rituximab
Refractory
Oncology
Pathology
Follicular phase
Mantle cell lymphoma
Mitoxantrone
Prospective cohort study
Internal medicine
Cyclophosphamide
Medicine
Cladribine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations